Clinical trials: Ticagrelor
Coronary Artery Disease
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
High on-treatment platelet reactivity (HOPR) is associated with increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI).
- Trial name
- OPTIMA-2 (NCT01955200)
- Testing
- Clopidogrel, Cilostazol, Ticagrelor
- Where
- China
- Volunteers
- 1,724 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Coronary Heart Disease
Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
This study was a feasibility trial that was designed to provide preliminary observations and generate hypotheses for future studies.
- Trial name
- NCT02219412
- Testing
- ticagrelor, Aspirin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Yong Huo
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Myocardial Infarction, Diabetes Mellitus
A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction
Taken together the results from CHARISMA and PEGASUS-TIMI54, it appears that physicians may consider extending beyond 1 year or reinitiating treatment with clopidogrel 75 mg od or ticagrelor 60mg bid in patients with a prior MI…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Renal Disease, Coronary Artery Disease
- Trial name
- ALTIC (NCT02663713)
- Testing
- Ticagrelor, Clopidogrel
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- University of Patras
Acute Coronary Syndrome, Angina, Unstable
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains elevated after a loading dose of ticagrelor at…
- Trial name
- NCT02925923
- Testing
- Ticagrelor, Eptifibatide, Clopidogrel
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Acute Coronary Syndrome
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
Ticagrelor is a potent and fast-acting P2Y12-ADP receptor antagonist recommended as first-line agent in ACS (2). This drug was associated with a 20% relative reduction in the rate of MACE in ACS patients undergoing PCI compared…
- Trial name
- TROUPER (NCT03357874)
- Testing
- Clopidogrel, Ticagrelor
- Where
- France
- Volunteers
- 259 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Myocardial Infarction, Diabetes Mellitus
Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction
Taken together the results from DAPT and PEGASUS-TIMI54, it appears that physicians may consider extending beyond 1 year or reinitiating treatment with a thienopyridine or ticagrelor 60mg bid in patients with a prior MI and…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Coronary Artery Disease, Renal Disease
- Trial name
- ALTIC-2 (NCT03387826)
- Testing
- Ticagrelor 60 mg, Prasugrel 5mg
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Attikon Hospital
Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent
Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )
The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill both orally administrated in decreasing…
- Trial name
- NCT01992523
- Testing
- Ticagrelor mashed pills, Ticagrelor integral pills
- Where
- 2 sites in Greece, Italy
- Volunteers
- 82 people
- Sponsor
- David Antoniucci
High Ischemic Risk
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous…
- Trial name
- NCT04989257
- Testing
- Ticagrelor-based dual-antiplatelet therapy, Clopidogrel-based dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,488 people
- Sponsor
- Yonsei University
Acute Coronary Syndrome, Interventional Cardiology
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events…
- Trial name
- LD-ASPIRIN (NCT04240834)
- Testing
- Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Healthy Volunteers
A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor
The study is an experimental observational study in ten healthy volunteers. Based on an in vitro study, it is hypothesize that a low dose epinephrine infusion will improve platelet function in healthy volunteers who have received…
- Trial name
- NCT03441412
- Testing
- Ticagrelor 90mg, Epinephrine, Metoprolol
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Pharmacokinetics
An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers
This will be a single centre study conducted at the 3rd hospital affiliated to Peking University. Approximately 24 healthy Chinese volunteers, male and female, will be recruited to obtain at least 20 evaluable volunteers.
- Trial name
- NCT00721448
- Testing
- AZD6140
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Ticagrelor in Fuwai Hospital
This is a single-arm non-interventional cohort study. This study is to describe the contemporary use of ticagrelor in a "real-world" setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety…
- Trial name
- TIFU (NCT02765711)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
STEMI, Morphine
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
This study will examine the impact of the peripheral opioid antagonist methylnaltrexone on the onset of effect of ticagrelor in morphine treated patients with ST elevation myocardial infarction (STEMI).
- Conditions
- STEMI, Morphine, Ticagrelor, Methylnaltrexone
- Trial name
- MOVEMENT (NCT02942550)
- Testing
- Methylnaltrexone bromide (Relistor®)., Sodium Chloride 9mg/mL
- Where
- 2 sites in Sweden
- Volunteers
- 82 people
- Sponsor
- Karolinska University Hospital
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Genotype and Platelet Reactivity in Patients on Hemodialysis
Patients with end stage renal disease (ESRD) on hemodialysis (HD) exhibited higher platelet reactivity to clopidogrel than did those with normal renal function.
- Trial name
- NCT02394145
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Kyunghee University Medical Center
Pharmacodynamics
Clopidogrel And Ticagrelor in Healthy Subjects
To evaluate the pharmacodynamics of a lower Ticagrelor dose in healthy Korean volunteers compared with standard Clopidogrel agent.
- Trial name
- NCT02086903
- Testing
- Ticagrelor 90 mg, Clopidogrel 600 mg
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Acute Coronary Syndrome
Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients
This is a retrospective, observational, descriptive study which will include patients hospitalized for acute coronary syndrome (ACS) and treated with ticagrelor at discharge.
- Trial name
- NCT04861363
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Peking University First Hospital
Coronary Artery Disease
In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Cangrelor is a potent intravenous P2Y12 receptor inhibitor with rapid onset and offset of action associated with a greater reduction in ischemic events, including stent thrombosis, in patients undergoing stent procedures who have…
- Trial name
- NCT02081443
- Testing
- Ticagrelor 180mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida